Glenmarks Ryaltris®- innovative single nasal spray, ready to market in Russia
MUMBAI, India, Feb. 22, 2021 /PRNewswire/ Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty S A, received marketing approval from the Ministry of Health of the Russian Federation for its innovative Ryaltris® Nasal Spray - a novel fixed-dose combination nasal spray.
This paves the way for commercialization of Ryaltris® in Russia which is expected to be made available to patients in the country in Q1 FY 2021-22.
Ryaltris® (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg) is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. Ryaltris® relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.
Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing
MUMBAI, India, Dec 23, 2020 /PRNewswire/ Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Menarini Group (Menarini) for commercializing its innovative nasal spray Ryaltris™ across 33 countries in Europe, including the Balkan region.
Ryaltris™ [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.